Target intelligence / Profile preview

Immunoglobulin light chain

Molecular classification
Other, Immune system protein component, Antibody subunit
01

Overview

The **immunoglobulin light chain** is a small polypeptide subunit that forms part of an antibody molecule. Each antibody consists of two identical heavy chains and two identical light chains, which together create the characteristic Y-shaped structure. The primary function of the immunoglobulin light chain is to contribute—along with the heavy chain—to forming the antigen-binding site at each arm tip through its variable region. There are two types in humans: kappa (κ) and lambda (λ), encoded by separate gene loci. Each B lymphocyte produces only one class—either κ or λ—for its lifetime. Light chains play a critical role in immune defense by enabling antibodies to specifically recognize diverse antigens. In healthy individuals, there is a typical serum ratio between kappa and lambda types; significant deviations may indicate clonal expansion seen in malignancies like multiple myeloma or lymphoma. Free circulating immunoglobulin light chains can be measured as biomarkers for these conditions. Pathologically increased levels may result from neoplastic plasma cells producing excess monoclonal free light chains, leading to their deposition in tissues—a hallmark feature of AL amyloidosis—or excretion into urine as "Bence Jones proteins." Elevated polyclonal free IgLCs also occur during inflammation but without clonal dominance. Immunoglobulin molecules—including their constituent heavy and **light** chains—are not direct drug targets but serve as important diagnostic markers for several hematologic diseases.

Other names
Ig light chainAntibody light chainLight chain (of immunoglobulin)IGK (for kappa type)IGL (for lambda type)
02

Biological functions

Antigen recognition and bindingImmune response mediationFormation of antigen-binding sites in antibodies
03

Disease associations

Cancer (notably multiple myeloma, lymphoma, leukemia)Autoimmune diseaseInfection/inflammatory diseases
04

Safety considerations

Accumulation can cause organ damage, especially kidney injury in amyloidosis or multiple myeloma due to deposition of free light chains ("Bence Jones protein")
05

Biomarkers

Serum free light chains (kappa and lambda) for diagnosis/monitoring of multiple myeloma and related plasma cell dyscrasiasKappa/lambda ratio for clonality assessment in lymphoproliferative disorders

Beyond the preview

Go deeper on Immunoglobulin light chain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin light chain.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call